18/5/2025, 8:19:02 pm

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

CRISPR Therapeutics' shares have dropped 24% over three years despite progress, but its gene-editing treatment Casgevy, targeting sickle cell disease and beta-thalassemia, could drive future growth. With a potential $1 billion+ annual sales, and promising pipeline candidates, the stock may rebound, offering significant returns by 2030, though it carries high risk.